These nanoparticles have demonstrated to be highly bioadhesive which allows to increase biavailability by obtaining a low toxic effect and high efficacy.
Adjuvant capacity by mucosal administration
These nanoparticles have demonstrated to improve antigen presentation to immunocompetent cells by mucosal administration (oral, intranasal, pulmonary…).
By mimicking the size of microorganisms (bacteria and viruses), these nanocarriers can be taken up by the immune cells and modulate their responses. This skill can be applied to develop vaccines or immunotherapy treatments for allergy diseases.